Advertisement
Advertisement
U.S. Markets close in 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

Ayala Pharmaceuticals, Inc. (AYLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.00+0.37 (+5.58%)
As of 03:49PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.63
Open6.82
Bid7.11 x 800
Ask7.17 x 900
Day's Range6.63 - 7.44
52 Week Range6.26 - 28.68
Volume118,568
Avg. Volume28,167
Market Cap97.547M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

    REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022. A webcast of the presentation will be ava

  • GlobeNewswire

    Ayala Pharmaceuticals Announces Key Business Objectives for 2022

    -- Data read-outs expected on AL102 in desmoid tumors and AL101 in ACC and TNBC --REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced its key objectives for 2022. “We believe that 2022 will be a pivotal ye

  • GlobeNewswire

    Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

    - Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 – - Presented Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC- - Published Case Studies Highlighting Clinical Activity of AL101 with Long-Lasting Responses in Patients with Desmoid Tumors – - Enrollment in All Ongoing Studies is on Track and Have Progressed as Planned – - Mult

Advertisement
Advertisement